Minerva Capital Research Solutions

Metropolis Healthcare

NSE: METROPOLISBSE: 542650
Compare with peers
₹ 553.00▲ 1.8 (+0.33%)29 Oct, 03:29 pm IST
Market cap
₹ 10,756 Cr.
P/E
54.9x
P/B
7.27x
52-week range
412.25 – 609.05
ROE
14%
ROCE
18%
Dividend yield
0.2%
Debt / equity
0.15
Sector
Healthcare Services
Industry
Healthcare Service Provider
Listed on
NSE, BSE

About

Metropolis Healthcare Limited is engaged in providing diagnostic services to patients, healthcare providers, and corporates across India and Africa. It has a single operating segment, namely Pathology services. It is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, other pathological and radiological investigations. Its services include Pathology Testing Services, Corporate Wellness, Lab In Hospitals and Clinical Research Services. It serves a diverse customer base, including B2C (Business to Consumer), B2B (Business to Business), and institutional clients. It offers more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. Its footprint spans 28 states, seven Union Territories.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Healthcare Service Provider: 36 companies →

Metropolis Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)54.9 against a typical 21: pricier than most peers (1st = cheapest).26th of 34
  • Sales growth+16.6% against a typical +19.1% from a year earlier.20th of 31
  • Profit growth+26.7% against a typical +25.2% from a year earlier.12th of 24
  • Share price, 3 months−5.5% against a typical −5.5%.16th of 33
  • Size₹ 10,756.2 Cr. market value against a typical ₹ 83 Cr. (1st = largest).3rd of 34

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

High safety

Rated AA- by CRISIL
AA-
DefaultRiskyModerateSafeVery safe
  • No warnings from the agency.
AgencyCurrent ratingOutlookAs of
CRISILCrisil AA-Positive22 Sep 2026
Credit rating actions
RatingDetails
22 Sep 2026
▲ Outlook raised
Crisil AA-
Outlook Stable → Positive
—CRISIL₹ 350 Cr.
24 Sep 2025
Rating action
Crisil AA-—CRISIL₹ 350 Cr.

Research by Minerva Capital Research Solutions

Our research team's work on Metropolis Healthcare

Also covered in

Diagnostics Sector
Sector note · 27 Mar 2025 · Free

Board meetings

Results dates and other board meetings. Full calendar

Details
3 Nov 2026UpcomingFinancial Results/DividendTo consider and approve the financial results for the period ended September 30, 2026 and dividend
4 Aug 2026Financial ResultsTo consider and approve the financial results for the period ended Jun 30, 2026
13 May 2026Financial Results/DividendTo consider and approve the audited financial results of the company for the quarter and financial year ended March 31, 2026 and dividend
4 Feb 2026BonusTo consider bonus
4 Nov 2025Financial Results/DividendTo consider and approve the financial results for the period ended September 30, 2025 and dividend
7 Aug 2025Financial ResultsTo consider and approve the financial results for the period ended Jun 30, 2025
13 May 2025Financial ResultsTo consider and approve the financial results for the period ended March 31, 2025

Share price

1Y change +13.78%
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales308291331313350323345386429406425450
Expenses234226251235260251283296321311317339
Operating Profit756580799072629010895108111
OPM %24%22%24%25%26%22%18%23%25%23%25%25%
Other Income123233781085
Interest656555556686
Depreciation222526262728293132323932
Profit before tax483751516142366171577078
Tax %26%26%28%25%24%26%19%26%26%26%27%27%
Net Profit362737384731294553425157
EPS in Rs1.731.331.781.852.271.531.412.172.5422.462.73

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
13%
5 Years
11%
3 Years
13%
TTM
22%
Compounded Profit Growth
10 Years
11%
5 Years
1%
3 Years
11%
TTM
37%
Stock Price CAGR
10 Years
—
5 Years
−5%
3 Years
18%
TTM
—
Return on Equity
10 Years
19%
5 Years
15%
3 Years
12%
TTM
—

Shareholding

Latest: Jun 2026.

Promoters
48.86%
−0.03 pts in a year
FIIs
11.03%
−1.8 pts in a year
DIIs
35.12%
+2.72 pts in a year
Public
5%
−0.87 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 54.9xEPS (12 months) ₹ 10.04Median P/E 58.3x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
Metropolis Healthcare₹ 553.00₹ 10,756 Cr.54.9x7.3x14%—
Apollo Hospitals Enterprise₹ 7,731.95₹ 1,11,174 Cr.64.9x13.4x22%7.8%
Max Healthcare Institute₹ 817.00₹ 79,519 Cr.71.5x9.9x14.3%17.2%
Fortis Healthcare₹ 720.00₹ 54,357 Cr.67.9x7.3x11.1%11.7%
Aster DM Healthcare₹ 651.00₹ 56,817 Cr.102.6x9.3x9.7%9.2%
Narayana Hrudayalaya₹ 1,667.25₹ 33,862 Cr.48.1x9.1x19.9%10.3%

Management

Ameera Sushil Shah
Executive Chairman of the Board
Surendran Chemmenkottil
Chief Executive Officer
Sameer Patel
Chief Financial Officer
Nilesh Jadavji Shah
President Internal Assurance and Advisor to Chief Executive Officer
Diya Suri
Chief People Officer
Pinakin Shah
Chief Information Officer
Mohan Menon
Chief Marketing Officer
Kirti Chadha
Chief Scientific Officer, Innovation Officer and Group Head CSR

Prices are delayed and for information only. Nothing on this page is investment advice.